Evaluating Real-Time Continuous Glucose Monitoring Versus Traditional Glucose Monitoring to Improve Blood Sugar Control in Adults Newly Diagnosed with Type 2 Diabetes

What this Trial Is About

Researchers are evaluating the use of real-time Continuous Glucose Monitoring CGM compared to standard Self-Monitoring of Blood Glucose SMBG in adults recently diagnosed with Type 2 Diabetes Mellitus T2DM. The study focuses on whether CGM can better improve blood sugar control, reduce glucose fluctuations, optimize metabolic parameters, and boost patient adherence to lifestyle and medication treatments during the early stages of T2D. This trial involves 80 adult patients diagnosed within the last 3 months, who may be managing their diabetes through lifestyle or stable non-insulin medications. Participants will be randomly assigned to one of two groups the CGM group will use a real-time CGM device for 28 days, while the control group will use traditional fingerstick glucometers for self-monitoring at least 2-3 times per week during the same period. Both groups will also receive educational materials and pedometers to track physical activity. After the 1-month active intervention phase, participants will be observed for an additional 2 months to assess ongoing effects. Throughout the 3-month study, participants will attend three outpatient visits at baseline, after 1 month, and at the end of 3 months. At these visits, researchers will collect data on blood markers like HbA1c and fructosamine, insulin resistance, lipid profiles, body measurements including BMI and waist circumference, physical activity levels, and quality of life through questionnaires. The study aims to determine the impact of CGM on glycemic control and lifestyle adherence compared to standard glucose monitoring methods.

DIabetes GLycemic Assessment in Newly Confirmed Episodes